Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Ardent Health, Inc. (“Ardent” or the “Company”) (NYSE: ARDT) securities between July 18, 2024 and November 12, 2025, inclusive (the “Class Period”). Ardent investors have until March 9, 2026 to file a lead plaintiff motion.

IF YOU SUFFERED A LOSS ON YOUR ARDENT HEALTH, INC. (ARDT) INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS

What Happened?

On November 12, 2025, after market hours, Ardent released its third quarter 2025 financial results, revealing a $43 million decrease in revenue. The Company explained it had “recently completed hindsight evaluations of historical collection trends” and as a result, had significantly negatively revised the collectability of certain accounts receivable.

Additionally, the Company reported a $54 million increase in professional liability reserves due to “recent settlements and ongoing litigations arising from a limited set of claims between 2019 and 2022 in New Mexico” as well as “broader industry trends, including social inflationary pressures.”

On this news, Ardent’s stock price fell $4.75, or 33.8%, to close at $9.30 per share on November 13, 2025, thereby injuring investors.

What Is The Lawsuit About?

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Ardent did not primarily rely on “detailed reviews of historical collections” in determining collectability of accounts receivable nor did “management determine . . . [when an] account is uncollectible.”; (2) the Company’s accounts receivable framework “utilized a 180-day cliff at which time an account became fully reserved,” which allowed Ardent to report higher amounts of accounts receivable during the Class Period, and delay recognizing losses on uncollectable accounts; (3) Ardent did not maintain professional malpractice liability insurance in amounts “sufficient to cover claims arising out of [its] operations”; (4) Ardent’s professional liability reserves were insufficient to cover “significant social inflationary pressure in medical malpractice cases the past several years,” which had been an “increasing dynamic year-over-year” in the Company’s New Mexico market; and (5) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you purchased or otherwise acquired Ardent securities during the Class Period, you may move the Court no later than March 9, 2026 to request appointment as lead plaintiff in this putative class action lawsuit.

Contact Us To Participate or Learn More:

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

Charles Linehan, Esq.,

Glancy Prongay & Murray LLP,

1925 Century Park East, Suite 2100,

Los Angeles California 90067

Email: shareholders@glancylaw.com

Telephone: 310-201-9150,

Toll-Free: 888-773-9224

Visit our website at www.glancylaw.com.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260114788354/en/